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Abstract 
Complement component C5 is the target of 
the monoclonal antibody Eculizumab, and the 
focus of a sustained drug discovery effort to 
prevent complement-induced inflammation in a 
range of autoimmune diseases.  
 The immune evasion protein OmCI binds 
to, and potently inactivates, C5; this tight-
binding interaction can be exploited to affinity-
purify C5 protein from serum, offering a vastly 
simplified protocol compared to existing 
methods. However, breaking the high-affinity 
interaction requires conditions which risk 
denaturing or activating C5.  
We performed structure-guided in silico 
mutagenesis to identify prospective OmCI 
residues that contribute significantly to the 
binding affinity. We tested our predictions in 
vitro, using site directed mutagenesis, and 
characterised mutants using a range of 
biophysical techniques as well as functional 
assays. Our biophysical analyses suggest the 
C5-OmCI interaction is complex with potential 
for multiple binding modes. 
We present single mutations that lower the 
affinity of OmCI for C5 and combinations of 
mutations that significantly decrease, or 
entirely abrogate, formation of the complex. 
The affinity attenuated forms of OmCI are 
suitable for affinity purification and allow 
elution under mild conditions that are non-
denaturing or activating to C5.  
We present the rational design, biophysical 
characterisation and experimental validation of  
 
 
affinity reduced forms of OmCI as tool reagents 
to enable the affinity purification of C5. 
 
 
Complement component C5 is a large, 188 
kDa protein which is integral to the 
complement system.  As an eventual 
consequence of activation of any of the 
classical, lectin or alternative pathways, C5 is 
cleaved into two functionally distinct moieties 
(1,2). The smaller anaphylatoxin subunit C5a 
signals via C5aR, a pro-inflammatory G-
Protein Coupled Receptor (3,4). The cleavage 
of C5a triggers a major conformational change 
in the C5d-CUB-MG8 superdomain, forming 
the metastable C5b subunit (5). The 
conformationally primed C5b can then 
assemble with C6-C9 to form the membrane 
attack complex, which results in the targeted 
lysis of pathogenic or damaged cells (6-8).  
Complement C5 has been targeted with 
various therapeutics, most notably by 
Eculizumab, a monoclonal antibody that binds 
to the MG7 domain of C5 (9,10) preventing 
cleavage by both the alternative pathway C5 
convertase (C3bBbC3b) or the classical and 
lectin pathways’ convertase (C4bC2aC3b) 
(1,2,10-12). Eculizumab is approved for the 
treatment of paroxysmal nocturnal 
haemoglobinuria (PNH) (13,14) and atypical 
haemolytic uraemic syndrome (aHUS) (15,16), 
and clinical studies are underway to expand into 
indications including age-related macular 
degeneration (17,18), myasthenia gravis 
(19,20), optic neuritis (21), and kidney 
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transplant rejection (22,23). Second generation 
therapeutics including affibodies, cyclic 
peptides, aptamers and small molecules that 
target C5 are currently in clinical or pre-clinical 
development (24,25). 
Intriguingly, parasites have also developed 
strategies of targeting C5 to evade lysis by the 
complement system. Two species of tick, 
Ornithodoros moubata and Rhipicephalus 
appendiculatus, have independently evolved 
salivary proteins that inactivate C5 when 
secreted during feeding (9,26-29). The two 
proteins, dubbed OmCI and RaCI after their 
respective species of origin, are of 
comparatively low molecular weight and are 
distinct in both sequence and structure.  
A crystal structure of the C5:OmCI:RaCI 
ternary complex (9) shows that both proteins 
bind at opposing ends of the C5d domain of C5, 
anchoring it to neighbouring domains. These 
sites are distant from the Eculizumab and Cobra 
Venom Factor binding sites on the MG7 
domain (10,30), and may prevent C5 activation 
by a different inhibitory mechanism. 
OmCI, a 17 KDa protein exhibiting the 
eight-stranded, antiparallel β-barrel fold 
characteristic of the lipocalin family, binds with 
the C5d and CUB domains of C5 (9,26). While 
it does not appear to have bonded interactions 
with the neighbouring, highly mobile C345C 
domain, such is their proximity that OmCI may 
still influence its conformational sampling.  
As a lipocalin, OmCI has evolved to interact 
with small hydrophobic molecules (31). In 
addition to preventing release of C5a, OmCI 
also sequesters the proinflammatory molecule 
leukotriene B4 (LTB4), making it a potent 
inhibitor of the early inflammatory response 
(27). A crystal structure of the OmCI/LTB4 
complex shows the aliphatic chain of LTB4 
bound within a conical binding cavity in the 
centre of the β-barrel fold (28). The pocket is 
comparatively promiscuous, also binding 
palmitoleic and elaidic fatty acids. OmCI can 
bind LTB4 and C5 simultaneously in a non-
cooperative manner (28). 
OmCI has broad cross-species reactivity and 
is being developed commercially in a modified 
form as Coversin (32), primarily targeting 
patients with the R885H mutation – a 
perturbation to the Eculizumab epitope which 
renders them resistant to treatment with the 
monoclonal antibody (33,34). 
Akin to C3 and C4, C5 is comparatively 
abundant in serum at a concentration of 75 
ug/mL (35). It expresses poorly in recombinant 
systems and is usually purified from serum. The 
standard protocol involves a serum 
precipitation step, followed by two sequential 
ion exchange purifications and a gel filtration 
step (36,37). Alternative purification 
approaches have been described, including 
hydrophobic interaction chromatography and 
immunoadsorption (38,39). Immunoadsorption 
is incumbent on the immunisation of animals to 
generate a polysera which, unless a monoclonal 
antibody is used, may not be a specific capture 
mechanism, with only a proportion of the sera 
being specific to C5 and with the potential for 
inconsistent performance due to batch 
variation. An additional complication is that 
changes in pH have been shown to activate C5 
and subsequently mild, non-activating elution 
conditions must be found to break the 
interaction with the antibody  (37).  
The C5-OmCI interaction has been 
previously exploited to purify C5 and OmCI 
complexes for crystallography (9). OmCI 
expresses extremely well in bacterial, yeast or 
mammalian cells, with a yield of 0.4g/L 
reported in yeast (28). It binds C5 with high 
affinity and, with suitable modifications to 
modulate affinity, could be an ideal 
recombinant tool with which to purify C5 from 
serum.  
The crystal structure allows computational 
energy calculations to guide the selection of 
residues to be attenuated using mutations to 
alanine or glycine. These rationally designed 
mutants may display differing affinities but also 
changing susceptibility to pH or ionic 
conditions, which may be exploited to create a 
specific recombinant reagent for affinity 
purification. If discovered, these reagents 
would markedly simplify the purification of 
complement C5 and aid academic and 
industrial research.  
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Results 
In silico design of affinity impaired OmCI 
mutants 
Using information from the crystal structure 
of the C5-OmCI-RaCI complex, we designed 
single residue mutations to reduce OmCI-C5 
affinity using Molecular Operating 
Environment (MOE) software (40,41) (Figure 
1). Mutations were ranked by the dAffinity 
score, a surrogate for binding free energy. 
Mutations predicted to lower the energy of the 
interaction more than 1 kcal/mol were found 
(Table 1).  
Notably, our analysis has selected charged 
residues that appear to participate in salt bridges 
or hydrogen bonds. Two hydrophobic residues, 
M134 and L140, were also identified. When 
mutating hydrophobic residues, we chose 
glycine mutations rather than alanine, to make 
a non-clashing mutation where hydrophobicity 
was entirely absent from the side chain. 
 
Validation of affinity impaired OmCI mutants 
To test our predictions, we made the 
following single residue mutations: R47A, 
H117A, M134G, L140G, E141A, H164A and 
D167A. In addition, a control F36W mutation 
was made. This mutation is patented as 
abrogating LTB4 binding without altering the 
affinity for C5 (42). We tested these OmCI 
mutants by SPR in single cycle kinetics 
experiments, with the aim of identifying a 
smaller panel of mutants to profile as a 
purification reagent. Single-cycle kinetics is 
performed by sequentially injecting increasing 
concentrations of analyte over the sensor chip, 
in the absence of any regeneration steps to 
remove bound analyte from the previous 
injection. 
The sensorgrams could be fitted using a 
single site binding model but were better 
explained by including additional parameters in 
a heterogenous ligand model. When using the 
single site binding model, comparatively low 
standard errors (SE), <0.2%, were observed 
when fitting the rate constants. However, 
visually, the model appeared to poorly estimate 
the on-rate (kon), overestimating the kon at lower 
concentrations and underestimating at higher 
concentrations (Figure S1).  
 Accordingly, we opted to rank the 
mutations based on changes in off-rate (koff), 
which was paramount for affinity purification 
(Table 1). Two mutations, E141A and M134G, 
had a significant effect on the stability of the 
OmCI-C5 complex.  The E141A mutation 
increased the koff value of the complex by ~29x 
and the M134G mutation by ~229x. However, 
we were concerned that the M134G mutant 
displayed low binding, relative to the amount of 
immobilised material, suggesting the protein 
had either been expressed with low activity or 
partially inactivated through amine coupling to 
the sensor chip. Other mutations had only 
modest effects on koff. The control F36W 
mutation, which is distal to the interface with 
C5, showed a small increase in koff value and 
displayed the same stoichiometric ratio of 
binding as wt OmCI. 
Our sensorgrams suggest that the OmCI-C5 
interaction is complex, and we chose to 
investigate further in multi-cycle kinetics 
experiments which are described later. 
  
Designing a suitable C5 purification reagent 
ligand based on combined OmCI mutations  
In order to further lower affinity, we 
modelled combinations of mutations. Again, 
we used MOE to simulate changes in binding 
energy (Table 1). Due to the potential for 
synergy, we retained mutations that had 
previously shown little effect in this second 
round of designs and based our final selection 
on the output of our MOE analysis.  
As predicted, combining mutations further 
abridge and, in some cases, entirely abrogate 
binding to C5. Combining either the H164A or 
R47A mutations with E141A produced OmCI 
variants with koff 197-973x faster than wt OmCI 
– characteristics favourable for application as 
affinity purification reagents, retaining fast 
association with C5, but with markedly 
increased dissociation.   
The largest effect was observed in the 
E141A/ R47A/ H164A/ L140G quadruple 
mutant, which produced a square wave 
sensorgram, more characteristic of the fast 
binding kinetics of a low molecular weight 
chemical fragment than a protein-protein 
interaction. The koff value of this protein was 
~5,500x higher than wt OmCI. The M134G 
mutation completely prevented binding when 
used in combination with E141A and R47A. 
 
Structural and functional analysis 
Circular Dichroism  
To look for gross changes in the secondary 
structure we used circular dichroism (CD). We 
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tested the E141A/ R47A and E141A/ H164A 
double mutants, alongside their constituent 
single mutants: E141A, R47A and H164A 
(Table 1). The M134G mutant, which markedly 
increased the koff value but significantly 
lowered binding, was also tested. The CD traces 
were closely comparable with wt OmCI, except 
for M134G, which showed a marked loss of 
structure at 217 nm consistent with an increase 
in random coil. Loss of the positive peak at 190 
nm was also observed, suggesting a loss of 
overall secondary structure (Figure S2).  
 
Differential Scanning Calorimetry 
We assessed the thermal stability of the 
mutants, their ability to refold after 
denaturation, and their capacity to stabilise C5 
when complexed using Differential Scanning 
Calorimetry (DSC). 
C5 displays a biphasic unfolding; the main 
peak unfolded at 60 oC, displaying a shoulder at 
69 °C, while a smaller, more stable domain or 
conformer unfolded at 77 oC (Table 2 and 
Figure 2). Upon complexing with OmCI the 
main peak was stabilised significantly with a 
ΔTm +8.6 oC. The mutants also increase the 
thermal stability of the main peak, with the 
degree of stabilisation reducing in agreement 
with their attenuated affinity.  
 The second peak may be stabilised upon 
OmCI binding, but the effect is smaller. The 
area under the peak, corresponding to the 
enthalpy of unfolding remains broadly the 
same, and the relationship to the affinity of the 
OmCI construct used is not as clear as observed 
with stabilisation of the main peak. 
The OmCI mutants are themselves typically 
less thermally stable than wt OmCI (Table 1, 
Figure 2 and Table S1). The most destabilising 
OmCI mutation was M134G, followed by 
R47A and E141A. The remaining mutants had 
comparatively modest ΔTm of <-3 oC. Of note, 
the E141A/ R47A double mutant was more 
thermally stable than wt OmCI, despite the 
single R47A and E141A mutations being 
amongst the most destabilising. 
We performed a cycle of cooling prior to a 
second melt to assess the ability of the proteins 
to refold after denaturation. The peak area 
corresponds to the enthalpy of unfolding (ΔH) 
and by taking a ratio of the two peaks a ΔΔH or 
percentage of refolding can be calculated. As a 
large, complex protein with numerous 
disulphide bonds, C5 was unable to refold, but 
a proportion of OmCI could recover and be re-
melted at a Tm almost identical to the first 
cycle. There was around a 72% recovery for wt 
OmCI with 47-69% recovery of the mutants. 
Consistent with the CD data, the M134G 
mutant was largely unable to refold with only 
24% of protein recovered.  
 
SPR - multi cycle kinetics 
Due to our observations when fitting data in 
our single cycle kinetics experiments, we 
looked for further evidence of complex binding 
kinetics in the C5-OmCI interaction. In order to 
obtain more detailed kinetic data for our 
analysis, we performed multi-cycle kinetics 
experiments by SPR. Multi-cycle kinetics 
performs a single injection of a single sample 
concentration within a cycle, regenerating the 
surface after each injection to dissociate bound 
material. To exclude heterogeneity in the 
immobilisation steps, OmCI was uniformly 
immobilised in a fixed orientation, using biotin 
conjugated to an N-terminal AVI tag.  
These data were explained by a single site 
binding model, with the fitting of kon generating 
broadly acceptable SE values. The refractive 
index changes upon binding did not suggest that 
the binding stoichiometry exceeded 1:1. 
However, consistent with our single cycle 
experiments, the single site binding model 
again appeared to underestimate kon at low 
concentrations and overestimate at higher 
concentrations (Figure 3). This suggests that 
observations in single cycle kinetics 
experiments were not the result of heterogenous 
immobilisation to the sensor chip and may 
indicate additional complexity in the OmCI-C5 
binding interaction.    
We report individual rate constants and KD 
values for the mutant OmCI proteins binding to 
C5 (Table 1, Figure 3 and Table S2). The wt 
protein exhibited antibody-like affinity, 
exceeding the 1.0E-5 s-1 limit for accurate 
determination of koff by SPR (43). In our 
experiments, the KD of wt OmCI is <100 pM, at 
least ten-fold lower than previously reported 
(28). The E141A single mutant displayed a >7-
fold decrease in affinity (KD of 0.7 nM), and the 
E141A/H164A double mutant displayed a >40-
fold decrease in affinity (KD of 4 nM).  Finally, 
the E141A/R47A double mutant displayed a 
>130-fold decrease in affinity (KD of 13 nM), 
relative to wt. Importantly, these decreases in 
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affinity were mediated by increases in the koff 
values.  
 
Complement Activation ELISA 
We tested the mutants in an Alternative 
Pathway (AP) activation ELISA to establish the 
extent to which affinity abridged forms of 
OmCI could inhibit formation of the MAC 
(Table 1, Table S3 and Figure S3). The single 
mutants and wt OmCI were potent inhibitors, 
displaying steep Hill slopes indicating that they 
had reached the tight binding limit of the assay. 
The double mutants, E141/ R47A and E141A/ 
H164A, showed a >10-fold and >5-fold loss of 
potency, respectively. Despite the variation in 
potency, all the mutants could effectively 
inhibit formation of the MAC at sufficiently 
high concentrations.  
 
Affinity purification of C5 with the E141A, 
H164A double mutant 
Having engineered faster dissociating forms 
of OmCI, we began to develop methods for the 
affinity purification of C5 from serum. OmCI 
proteins were biotinylated via an N-terminal tag 
and captured on a streptavidin column. 
Fractionated serum was applied to the column 
and conditions for the elution of C5 were tested.  
With wt OmCI (koff =<1.0E-5 s-1), C5 was 
captured but would not elute with either 2M 
NaCl or 3M MgCl2. Using a pH gradient, C5 
was eluted at approximately pH 2.8, where it 
formed a milky precipitate which could be 
reversed upon neutralisation with 1M Tris.  
Working to the ‘Goldilocks principle’, we 
hoped to identify a mutant with the ideal kinetic 
profile to permit capture of C5 but with a 
suitably attenuated koff to allow the interaction 
to be destabilised and eluted under mild 
conditions.   
We ran small scale purifications, trialling 
the mutants as capture reagents in order of their 
faster dissociation. The E141A single mutant 
(koff =3.0E-04 s-1) would not permit elution with 
either NaCl or MgCl2. The abridged affinity had 
only a modest effect on the pH gradient, with 
C5 still eluting around pH 2.8. 
The E141A/ H164A double mutant (koff 
=4.0E-03s-1) was the next mutant trialled as an 
affinity purification reagent. With this mutant, 
C5 was captured and then eluted with either 2M 
NaCl or 3M MgCl2. C5 did not respond 
favourably to elution with high NaCl, 
irreversibly precipitating when eluted at 2M 
and eluting at 1M in a broad, flat peak. 
Conversely, 3M MgCl2 gave a sharp, 
symmetrical elution peak with no visible 
precipitation in the fractions. We tested lower 
concentrations of MgCl2 and found we could 
elute C5 using a 2M solution, but with a 1M 
solution tailing of the peak was observed.  
After a gel filtration step we tested the 
purified C5 to ascertain its quality and 
functional activity (Figure 4). The final material 
was pure by SDS PAGE, the thermal melt was 
consistent with commercially available C5 by 
DSC, and it bound to wt OmCI with high 
affinity, <100 pM, in a multi-cycle kinetics 
experiment. Crucially, the material was 
functionally active and restored activity to C5-
depleted serum in an AP activation ELISA, 
with a pEC50 of 7.1 -log M.   
The E141A/R47A double mutant (koff 
=3.2E-02 s-1) proved to have too fast a 
dissociation rate to retain C5 on the column 
prior to elution.  
 
Discussion 
In silico and biophysical analysis of the C5-
OmCI interaction has identified residues that 
contribute significantly to the high binding 
affinity. We show that the OmCI-C5 interaction 
is complex and higher affinity than previously 
thought, and we demonstrate the utility of 
affinity attenuated OmCI as a purification 
reagent. 
The in silico mutagenesis, performed using 
MOE, identified seven residues which could 
significantly alter binding energy, including 
five charged residues that potentially contribute 
to the formation of either salt bridges or 
hydrogen bonds.  
The C5-OmCI-RaCI crystal structure 
suggests there are two ionic interactions 
between C5 and OmCI, arising from a bidentate 
salt bridge between E141OmCI and R1226C5. 
Experimentally, E141A was the most effective 
single mutation, which highlights the 
importance of the salt bridge interactions.  
The other polar residues lack suitably 
charged opposing residues on C5 with which to 
make ionic interactions, and instead make inter-
chain hydrogen bonds. In the structure, 
H164OmCI and H117OmCI appear to make 
hydrogen bonds with the backbone carbonyl 
groups of P1221C5 and S1236C5, respectively. 
Two residues appear to make bidentate 
hydrogen bonds: D167OmCI with the backbone 
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amide groups of R955C5 and R956C5; and 
R47OmCI with the side chain carbonyl and amide 
groups of N1221C5. 
Experimentally, the rank order of affinity of 
the hydrogen bonding residues was broadly as 
per the predictions in MOE, with the KD of 
H164A < D167A< H117A. However, our 
analysis in MOE overestimated the impact of 
the H164A mutation relative to removal of the 
E141 salt bridge and underestimated the 
importance of the R47A mutation. The H164A 
mutation was predicted to be the most 
attenuating single mutation but it was found to 
be less effective than either E141A or R47A. 
Two hydrophobic residues, M134OmCI and 
L140OmCI, were also identified in the MOE 
analysis. Both are adjacent to charged residues 
(D135OmCI and E141OmCI respectively), and may 
have been identified as either lowering the 
desolvation or conformational entropy of their 
polar neighbours. We had predicted that L140G 
would be the third most effective mutation, but 
as a single mutation it was largely ineffective 
and made only a modest contribution when 
used in combination. 
The single M134G mutation virtually 
attenuated binding, but CD and DSC data, 
suggest this is likely to be due to instability 
arising from a loss of secondary structure. 
M134 is at the end of a β-sheet and the insertion 
of a flexible glycine residue may be poorly 
tolerated in this position.  
M134 marks the end of BH-α3, a 
predominantly hydrophobic loop on which 
L140G is situated, connecting the large α3 helix 
of OmCI to the β-barrel fold. In complex with 
C5, this loop nestles in a hydrophobic channel 
on the C5d domain, bordered by A1216C5-
V1218C5 and S123C5-V1239C5. Although the 
region is hydrophobic, inter chain hydrogen 
bonds appear to form between the backbone 
moieties. These are not side chain interactions 
and subsequently could not be easily 
investigated by mutagenesis, but they may still 
contribute significantly to the free energy of 
binding, with the hydrophobic environment 
ensuring a low desolvation entropy.  
Finally, the control mutation, F36WOmCI, 
showed only a slight increase in koff value, as 
expected. While this mutant still displayed high 
affinity binding to C5, this may indicate a subtle 
allosteric effect arising from this distal 
mutation. 
Overall the structure-based in silico 
approach was effective in designing mutations, 
reducing the number of mutants that had to be 
made and tested. While there were some 
notable outliers in the ranking there is a 
reasonable correlation with our experimental 
data.   
When considering binding modes, our 
single-cycle kinetics experiments suggested the 
potential for a complex interaction, that while 
displaying refractive index changes consistent 
with a 1:1 stoichiometry, was not best described 
with a one site binding model. We performed 
multi-cycle kinetics, with site specific 
immobilisation of OmCI via an N-terminal tag, 
and observed similar outcomes when fitting 
data using the single site binding model, 
suggesting that the complex kinetics are not the 
result of a heterogenous immobilisation. Both 
the C5d and CUB domains interact with OmCI 
and this creates the potential for multiple 
binding modes should an interaction with either 
domain be made first.  
C5 displays a biphasic unfolding when 
thermally denatured. A main peak unfolds at 60 
oC, with a shoulder at 69°C, and a second 
smaller unfolding occurs at 77 oC. The shoulder 
of the main peak observed in C5 may be of 
interest, as it closely matches the Tm of the 
main peak in the C5-wt OmCI complex. This 
may suggest that OmCI is selecting a naturally 
occurring C5 conformation in which C5 is 
resistant to cleavage by the C5 convertases.   
The smaller unfolding at 77 oC may also 
arise from a conformer of C5. If this is the case, 
the small size of the peak, corresponding to the 
enthalpy of unfolding, would suggest that the 
conformation is infrequently sampled. While 
OmCI may bind to and stabilise the conformer, 
increasing Tm, the ΔH remains broadly 
consistent which suggests it is not a 
conformation that OmCI selects for or induces. 
Alternatively, this could be a more stable 
domain that is structurally distinct from the MG 
domains which constitute a large proportion of 
C5, potentially either the C5d, CUB or C345C 
domains.  Complexing with OmCI appears to 
stabilise this domain by +3 oC but there is not a 
clear correlation to affinity when complexed 
with mutant OmCI. The lack of correlation to 
affinity could indicate an interaction between 
C5-OmCI that is not within the binding 
interface, as seen in the crystal structure, and 
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therefore is not attenuated by our mutations 
provided full occupancy is maintained.  
When looking at the charge profile of the 
surface of C5 and OmCI we noted a positively 
charged cavity between the C5d and CUB 
domains (Figure S4). The surface of OmCI is 
negatively charged and there may be further 
complementary charge interactions with this 
cavity that are prevented by F1631C5 protruding 
from the C345C domain and occluding the 
cavity (Figure 1A). The position and proximity 
of the flexible C345C domain appears to be the 
result of crystal contacts between C5 
molecules, rather than a specific interaction 
with the OmCI protein, suggesting that this 
positively charged region on C5 may be 
accessible in solution.  
When testing our mutants in AP ELISA, we 
did not see reductions in Emax as a result of 
removing contacts which would have indicated 
allosteric inhibition. Our mutants behave in the 
functionally competitive manner of the wt, 
which could indicate a competitive or steric 
mechanism for OmCI inhibition.   
Our affinity attenuated forms of OmCI are 
useful tools for the purification of C5; they are 
highly expressed and able to refold after 
complete denaturation at 100oC. It is fortunate 
that the mutations decreased koff specifically, 
with only modest effects on kon, and as such are 
ideal capture reagents for affinity columns. Our 
final purification reagent, E141A, H164A 
OmCI, is thermally stable and resilient to 
denaturation. The elution conditions this 
mutant has enabled are comparatively gentle, 
with no evidence of C5 activation with short 
term exposure to 2M MgCl2. This reagent will 
be a valuable tool for the purification of C5 to 
support research and drug discovery.  
 
Experimental Procedures 
 
Design of mutations 
Molecular Operating Environment (MOE 
2016.08) was used to virtually mutate 
individual OmCI residues to alanine in the 
crystal co-complex structure of OmCI-C5 
(PDB code: 5HCC). The effect of these changes 
on the C5 interaction were scored using a 
binding free energy prediction (dAffinity). 
Alanine and glycine mutations that lowered 
dAffinity by more than 1 Kcal/mol were 
selected for experimental validation. 
 
Construct design 
A DNA sequence, comprising the wt OmCI 
reference sequence (Uniprot entry: Q5YD59), 
with a n-terminal AVI-tag peptide sequence 
(GLNDIFEAQKIEWHE) and poly-Histidine 
tag, was designed using Vector NTI. In total 15 
gene variants were designed with single or 
double mutations to validate the in silico 
affinity predictions. The amino acid sequence 
of the OmCI proteins can be found in Figure S5.  
Custom synthesis and cloning into a 
mammalian expression vector was performed 
by ATUM.  
 
Small scale expression and purification 
Plasmid DNA for each construct was 
amplified using QIAGEN Plasmid Plus Giga 
Kits and quantified by A260. Individual 50ml 
ExpiHEK 293 cell cultures, at 3x106 cells/mL, 
per construct, were set up using Expifectamine 
293 Transfection kits (Invitrogen), as per the 
manufacturer’s instructions. The cells were 
cultured for four days and centrifuged at 4000 
rpm for one hour. 
The supernatants were filtered through a 
0.22 µm sterifilter and each sample purified on 
1.0 mL of Ni Sepharose® Excel capture resin 
(GE Healthcare). The following modifications 
were made to the manufacturer’s protocol: after 
binding, affinity captured protein was washed 
with 20x resin volume using Buffer A (0.5 M 
NaCl, 0.02 M Imidazole, PBS pH 7.3). Protein 
samples were then eluted using Buffer B (0.5 M 
NaCl, 0.25 M Imidazole, PBS (pH7.3) as 10x 2 
mL fractions. Post elution, the proteins were 
concentrated and buffer exchanged using 10 
kDa spin concentrators (MerckMillipore). The 
protein concentration was determined by A280 
and the samples were analysed by SDS PAGE 
before storage at -80 oC. 
 
Bir-A biotinylation of AVI tagged OmCI 
Biotinylation of the n-terminal AVI tag was 
performed using a Bir-A labelling kit (Avidity), 
as per manufacturer’s instructions. OmCI 
protein was buffer exchanged in 10mM Tris, 
pH 8.0, using 2mL Zeba desalting columns 
(Thermo Fisher) and diluted to 40 µM. Bir-A 
enzyme was added at 11.625 ug/mL and 
BioMix B was added at 10% (v/v). An 
overnight incubation at RT was performed. 
Prior to use, unreacted biotin was removed 
using a PD-10 desalting column (GE 
Healthcare).  
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Surface Plasmon Resonance – single-cycle 
kinetics 
Experiments were performed using a 
Biacore 8K (GE Healthcare). The OmCI 
mutants were immobilised on a CM5 chip using 
amine coupling. To achieve a minimal 
immobilisation both flow cells were activated 
using EDC/NHS at a 1:2 molar ratio (flow rate 
10 µL/min, contact time 30 s). Solutions of 
OmCI at 1 ug/mL were prepared in pH 4.5 
Sodium acetate buffer and immobilised on flow 
cell two only (flow rate 10 µL/min, contact time 
420 s). Finally, ethanolamine was applied to 
both flow cells (flow rate 10 µL/min, contact 
time 420 s). A final immobilisation level of ca 
50 RU was obtained. 
Single-cycle kinetics were measured using a 
nine point, three-fold titration of C5 
(CompTech) from 500nM in HBS-EP buffer. A 
high flow rate of 40 µL/min was used, with a 
contact time of 230 s and a dissociation time of 
900 s. Binding to the reference surface was 
subtracted and data fitted to a single site 
binding model, using Biacore Evaluation 
Software. 
 
Differential Scanning Calorimetry 
DSC was performed using a Malvern Microcal 
VP Capillary DSC. Samples of C5 (CompTech) 
and OmCI protein were diluted to 1 mg/mL in 
PBS. For complexing experiments, C5 and 
OmCI were mixed in 1:1.25 molar ratio and 
incubated for a minimum of six hours at 4 oC. 
Samples were heated from 10oC to 100oC at a 
rate of 1oC/min. The injection speed was 50uL/s 
with three filling strokes used. Six buffer reads 
were measured prior to running samples and a 
clean, consisting of three cycles of 20 minute 
detergent incubations at 80 oC, was performed 
after each sample. For refolding experiments, 
after cooling for 1 hour, a single rescan was 
performed under the same analysis parameters. 
Data were analysed using Origin 7.0 software 
and fitted using a non-two state, cursor initiated 
model.  
 
Circular Dichroism 
OmCI protein was buffer exchanged into 20 
mM phosphate, pH 7.4, 150 mM NaF using 0.5 
mL Zeba desalting columns (Thermo Fisher). 
CD spectra were acquired using a scan range of 
185-260nm, with a step size of 0.5nm, a time-
per-point of 1s and a bandwidth of 1nm. The 
concentration of protein was 0.3mg/mL and the 
cuvette pathlength was 1.0 mm. 
An air blank was measured and 
automatically subtracted and a buffer blank was 
measured and manually subtracted from the 
spectra. 
 
Surface Plasmon Resonance- multi-cycle 
kinetics  
Multi cycle kinetics were measured using a 
Biacore 8K (GE Healthcare). Site specifically 
biotinylated OmCI protein was diluted to 5 nM 
in HBS-EP. Both flow cells of an SA 
strepatvidin chip were prepared by performing 
three sequential injections of 1M NaCl, 20mM 
NaOH (flow rate 10 µL/min, contact time 60 s). 
OmCI was then injected over flow cell 1 (flow 
rate 10 µL/min, contact time 60 s). Final 
immobilisation levels in the range of 20-100 
RU were obtained. A wash of the fluidics with 
a 1:1 mixture of isopropanol and 1M NaCl, 
20mM NaOH was performed, prior to running 
samples.  
A seven point, three-fold titration of C5 
(CompTech) was prepared in HBS-EP buffer 
from 250nM. This was injected at a flow rate of 
30 µL/min, with a contact time of 240 s and a 
dissociation time of 3600 s. After each 
injection, the surface was regenerated with two 
sequential injections of 0.1M citric acid 
monohydrate (pH 2.0) with a contact time of 30 
s and flow rate of 30 µL/min.  
Binding to the reference surface was 
subtracted and data fitted to a single site 
binding model, using Biacore Evaluation 
Software. When fitting data, curves at 
concentrations >18.5nM (20-200x [KD]) were 
excluded from the analysis to maximise 
curvature and increase the accuracy of fitting 
Kon.  
 
Complement Activation ELISA 
An Alternative Pathway Complement 
ELISA (Wieslab) was run as per the 
manufacturer’s instructions. Ten point, three-
fold titrations of OmCI were made from 5 µM 
in human serum (TCS Bioscience) and allowed 
to incubate for 30 minutes at RT, prior to 
receiving a 1/18 dilution into assay diluent. The 
diluted samples were immediately plated onto 
the assay plate.  
For experiments with purified C5, C5 was 
titrated from 5 µM in C5 depleted serum 
 at U
CB PH
A
RM
A
 on Septem
ber 11, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The rational design of affinity attenuated OmCI 
9 
 
 
(Comptech), immediately diluted 1/18 into 
assay diluent and plated. 
Data was analysed using a 4-parameter 
logistic fit in Prism 7.02. 
 
Ammonium sulphate precipitation 
 Human serum (TCS Bioscience) was 
thawed in a 37oC water bath. The serum was 
cooled to 4oC and 60mL of a saturated 
ammonium sulphate solution was added 
dropwise per 100mL of serum, with gentle 
stirring. The precipitate was collected by 
centrifugation at 10,000 xg for 30 minutes at 4 
oC. The pellet was resuspended to the original 
serum volume using PBS, 10mM EDTA and a 
second round of precipitation performed. Prior 
to loading on the column, the sample was 
filtered through a 0.22 µM sterifilter.  
 
Purification of C5 using affinity attenuated 
OmCI 
Using an Akta pure (GE Healthcare), 
biotinylated E141A, H164A OmCI was diluted 
to 20 µM and 2.0mL was injected onto a 1mL 
Hi-Trap Streptavidin HP column (GE 
Healthcare) at a flow rate of 0.5mL/min.  
The column was equilibrated with 5x 
column volumes (CV) of PBS. Ammonium 
sulphate precipitated serum was loaded at a 
flow rate of 0.5 mL/min and a 5x CV wash with 
PBS at a flow rate of 1mL/min was performed. 
C5 was eluted and collected in fractions, using 
an isocratic elution of 5x CV 20mM Tris, 2M 
MgCl2, at a flow rate of 1mL/min.    
Immediately after elution, the fractions were 
pooled and injected onto a HiLoad 16/600 
Superdex 200 pg gel filtration column (GE 
Healthcare), that had been pre-equilibrated with 
PBS. The column was run at 1mL/min and all 
peaks were collected. The peaks were analysed 
by SDS PAGE and those with a molecular 
weight consistent with C5 monomer were 
pooled and stored at -80 oC. 
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Table 1 
Summary table of key data generated with OmCI proteins, showing the selection of a small panel of mutants for profiling as a purification ligand.  
 
 
1 Single cycle kinetics sensorgrams are shown in Figure S1. A nominal fold change relative to wt koff (approximately 1.0E+05 Ms-1) is shown to exemplify 
changes in stability of OmCI-C5 complex. 
2 ΔTm values are relative to the wt OmCI protein. Data are shown in Table S1 and Figure 2. 
3 NB = no binding detected. 
 
 
 
In silico 
prediction 
Single-
cycle kinetics 1 CD DSC
2              AP ELISA Multi-cycle kinetics 
OmCI  
Mutation 
dAffinity 
score (kcal/ 
mol) 
Approximate 
fold change in 
koff  
Loss of 
secondary 
structure  
(217 nm) 
ΔTm 
(oC) 
ΔΔH (% 
refolded) 
pIC50  
(-log M) 
kon 
(1/Ms) 
koff  
(1/s) 
KD  
(M) 
Wild type OmCI - - N - 71.7 ≤ 9.0 5.88E+05 <1.0E-05 <1.0E-10 
F36W 0 2.6        
D167A 1.9 2.4        
H117A 2.3 1.1        
R47A 3.1 4.1 N -4.8 69.1 ≤ 9.0    
M134G 4.3 229.0 Y -8.2 23.9     
L140G 5.4 1.0        
E141A 5.8 29.1 N -3.3 61.7 ≤ 8.9 4.81E+05 3.04E-04 7.09E-10 
H164A 7.6 3.5 N -1.6 57.7 ≤ 8.8    
E141A/ R47A 9.3 973.0 N 3.1 54.1 8.0 3.01E+06 3.18E-02 1.31E-08 
E141A/ H164A 11.3 197.0 N -1.8 47.8 8.5 1.13E+06 4.06E-03 4.09E-09 
E141A/ L140G 12.8 31.3        
E141A/ R47A/ M134G 14.6 NB3        
E141A/ R47A/ L140G 15.4 1270.0        
E141A/ R47A/ H164A/ L140G 20.4 5500.0        
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Table 2 
DSC data on C5:OmCI complexes. Data from n=1 experiment. 
Sample Peak 1 Tm (oC) 
Peak 1 
ΔH (cal/M) 
Peak 2 Tm 
(oC) 
Peak 2 
ΔH (cal/M) 
C5 60.31 ± 0.012 8.1E+05 77.06 ± 0.21 1.1E+05 
C5:wt OmCI 68.90 ± 0.020 7.1E+05 81.36 ± 0.21 7.8E+04 
C5:E141A OmCI 67.99 ± 0.019 9.6E+05 80.83 ± 0.33 8.1E+04 
C5:E141A/ R47A OmCI 66.68 ± 0.016 9.1E+05 80.96 ± 0.28 5.6E+04 
C5:E141A/ H164A OmCI 65.41 ± 0.011 8.8E+05 80.49 ± 0.27 5.3E+04 
 
 
Figure 1. Molecular interactions of the C5-OmCI complex. Panel A shows OmCI in complex with 
the C5d and CUB domains, on the C5d-CUB-MG8 superdomain of C5 (PDB code: 5HCC). Panel B 
shows the surface of C5 coloured by charge, with red denoting areas of negative charge and positively 
charged areas shown in blue. The two OmCI residues that contribute significantly to binding affinity, 
E141 and R47, are shown. Panel C shows the residues identified from our in silico mutagenesis study 
as contributing significantly to binding affinity, with panel D showing the 180° view. 
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Figure 2. DSC thermograms for C5 alone and in complex with OmCI proteins. C5 displays a 
biphasic unfolding, the main peak has a slight shoulder and unfolds at 60.3 oC, with a smaller and more 
stable peak unfolding at 77.1 oC. Complexing C5 with OmCI stabilises the main peak, in proportion to 
the binding affinity (panel A). A smaller stabilisation effect, ΔTm = +3 oC, is observed on the second 
peak but without clear correlation to the affinity of OmCI construct (Panel B). Panel C shows DSC 
thermograms for OmCI proteins. The first round of melting is shown in black with the second melt 
shown in orange. The peak area corresponds to the enthalpy of unfolding (ΔH) and by taking a ratio of 
the two peaks a ΔΔH or percentage of refolding can be calculated.    
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Figure 3. Sensorgrams from multi cycle kinetics. The sensorgrams above show raw data (coloured 
by concentration) and the fit from a single site binding model (in black). The mutants display an 
accelerated dissociation relative to wt OmCI. Fitting with the single site model appears to 
underestimate kon at low concentrations, while at higher concentrations it appears to overestimate it.  
 
Figure 4. Purification of functional C5 with affinity attenuated E141A/ H164A OmCI mutant. 
Panel A shows the elution of C5 from an E141A/ H164A OmCI column using isocratic elution with 
2M MgCl2, after one column volume the material elutes in a sharp and broadly symmetrical peak. Panel 
B shows elution of affinity purified C5 from a gel filtration column as a single peak with a small high 
molecular weight peak. Panel C is a reduced (R) and non-reduced (NR) SDS PAGE gel of the material, 
pre and post affinity purification and gel filtration (5ug of the final C5 sample is loaded). A thermal 
melt of the protein by DSC is shown in panel D, with a Tm of 59.9 oC for the main peak. The ability of 
the material to restore complement activation to C5-depleted serum, with a pEC50 of -7.1 -log M, is 
shown in panel E. Finally, binding of our purified C5 to wt OmCI is shown in a multi-cycle kinetics 
experiment, with a KD <100 pM in Panel F. 
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Supplementary Information 
 
 
 
Figure S1. Example Sensorgrams from single cycle kinetics experiments, fitted with a one site 
binding model. The sensorgrams are shown in blue and the fit in red. The mutants show an 
accelerated koff during the dissociation phase.  
 
 
 
Figure S2. CD traces of OmCI proteins. All mutants show similar profiles by CD apart from 
M134G, which shows a marked loss of structure at 217nm consistent with a loss of β sheet. A 
reduction in the positive peak is also observed suggesting a loss of overall secondary structure.  
 
 
 
 
  
Table S1 
DSC data for OmCI proteins. Data from n=1 experiment. 
 
 
 
  
 
Mutation Tm (
oC) ΔTm (oC) 
ΔH 
(Cal/M) 
ΔΔH (% 
refolded) 
wt OmCI  64.39 ± 0.015 - 6.2E+04 - 
wt OmCI refold 64.47 ± 0.016 +0.1 4.5E+04 71.7 
R47A 59.56 ± 0.015 -4.8 4.9E+04 - 
R47A refold 59.44 ± 0.012 -5.0 3.4E+04 69.1 
E141A 61.08 ± 0.011 -3.3 5.7E+04 - 
E141A refold 62.11 ± 0.011 -2.3 3.5E+04 61.7 
H164A 62.8 ± 0.013 -1.6 9.2E+04 - 
H164A refold 62.63 ± 0.011 -1.8 5.3E+04 57.7 
E141A/ R47A 67.46 ± 0.011 +3.1 1.0E+05 - 
E141A/ R47A refold 68.02 ± 0.006 +3.6 5.5E+04 54.1 
E141A/ H164A 62.64 ± 0.015 -1.8 9.9E+04 - 
E141A/ H164A refold 62.61 ± 0.001 -1.8 4.8E+04 47.8 
M134G 56.18 ± 0.001 -8.2 4.6E+04 - 
M134G refold 56.94 ± 0.001 -7.5 1.1E+04 23.9 
Table S2 
Multi cycle kinetics data summary table. Data from n=4 experiments unless stated. 
*average from n=3 experiments 
 
Multicycle kinetics data from individual occasions 
 
n=1 
 kon (1/Ms) Kon SE koff (1/s) Koff SE KD (M) 
OmCI WT 3.84E+05 5.31E+01 <1.0E-05 - <100pM 
OmCI E141A 3.67E+05 9.25E+01 3.07E-04 2.07E-08 8.37E-10 
OmCI E141A R47A 9.86E+05 8.49E+02 1.78E-02 5.49E-09 1.80E-08 
OmCI E141A H164A 8.55E+05 4.18E+03 4.38E-03 6.37E-08 5.13E-09 
 
n=2 
 kon (1/Ms) Kon SE koff (1/s) Koff SE KD (M) 
OmCI WT 4.00E+05 6.00E+01 <1.0E-05 - <100pM 
OmCI E141A 3.43E+05 3.08E+02 3.07E-04 2.30E-07 8.96E-10 
OmCI E141A R47A 1.19E+06 1.33E+03 2.09E-02 2.25E-05 1.76E-08 
OmCI E141A H164A 9.13E+05 4.38E+03 4.89E-03 2.41E-05 5.35E-09 
      
 
n=3 
 kon (1/Ms) Kon SE koff (1/s) Koff SE KD (M) 
OmCI WT 1.14E+06 5.79E+02 <1.0E-05 - <100pM 
OmCI WT E141A 8.30E+05 3.00E+02 3.28E-04 1.68E-07 3.95E-10 
OmCI E141A R47A 2.43E+06 2.50E+03 1.76E-02 1.70E-05 7.26E-09 
OmCI E141A H164A 1.62E+06 1.66E+03 2.92E-03 2.45E-06 1.80E-09 
 
n=4 
 kon (1/Ms) Kon SE koff (1/s) Koff SE KD (M) 
OmCI WT 4.32E+05 6.36E+01 <1.0E-05 - <100pM 
OmCI E141A 3.86E+05 8.19E+02 2.73E-04 4.04E-07 7.07E-10 
OmCI E141A R47A 7.44E+06 3.19E+05 7.11E-02 3.07E-03 9.55E-09 
OmCI E141A H164A* ND ND ND ND ND 
 
*Curve rejected.   
 kon (1/Ms) kon 95% CI koff (1/s) koff 95% CI KD (M) 
wt OmCI 5.88E+05 3.60E+05 <1.0E-05 - <100pM 
E141A 4.81E+05 2.28E+05 3.04E-04 2.20E-05 7.09E-10 
E141A R47A 3.01E+06 2.96E+06 3.18E-02 2.57E-02 1.31E-08 
E141A H164A* 1.13E+06 4.18E+05 4.06E-03 1.16E-03 4.09E-09 
Supplementary Table 3 
Alternative pathway activation ELISA.  Data from n=3 experiments.  
Mutant  ࢞ ഥ pIC50 pIC50 
range (n=3) 
࢞ഥ Hill 
Slope 
࢞ഥ Emax (%) 
wt OmCI ≤ 9.0  9.0-9.1 >5 99.8 
R47A ≤ 9.0 8.9-9.1 3.9 99.1 
E141A ≤ 8.9 8.9 2.4 98.7 
H164A ≤ 8.8 8.8 2.5 100.2 
E141A/ R47A 8.0 8.0-8.1 0.9 94.7 
E141A/ H164A 8.5 8.5-8.6 1.3 97.6 
 
 
Supplementary Figure 3 Inhibiton of MAC formation in an Alternative Pathway ELISA. The 
ability of the OmCI mutants to inhibit formation of the MAC was tested by ELISA. The wt protein 
and single mutants are potent inhibitors and display steep hill slopes. All proteins show full efficacy 
with Emax values ~100%.   
 
  
 
Figure S4. Surface charges of C5 and OmCI. Panel A shows the C5d-CUB-MG8 superdomain of 
C5 in complex with OmCI (PDB code: 5HCC), the surface is coloured by charge, with blue denoting 
areas of positive charge and negatively charged areas shown in red. OmCI is predominantly 
negatively charged. Panel B shows a close-up view of OmCI and C345c showing the non-bonded 
contact between the two, with a positively charged cavity visible between C5d and CUB domains.  
Panel C shows the C5d-CUB-MG8 superdomain from the apo C5 structure (PDB code 3CU7) in 
place of the superdomain from the OmCI-RaCI-C5 structure used in panels A and B. The positively 
charged cavity is accessible to OmCI when C345C is in the ‘down position’.  
 
  
 
 
Figure S5. Amino acid sequence of OmCI constructs. The amino acid sequence of the final OmCI 
constructs is shown above. The residues comprising the N-terminal tags are coloured as follows: the 
10x Histidine tag in green, a TEV cleavage site in pink and an AVI site in yellow. The residues 
mutated in the study are coloured cyan. 
